Skip to main content
Erschienen in: Die Innere Medizin 4/2009

01.04.2009 | Schwerpunkt: Hypertonie

Leitliniengerechte Differenzialtherapie der Hypertonie

verfasst von: Prof. Dr. K.H. Rahn

Erschienen in: Die Innere Medizin | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Zusammenfassung

Ziel der Hochdruckbehandlung ist es, den Blutdruck zu senken und dadurch das kardiovaskuläre Risiko der Patienten zu verringern. Für diese Therapie stehen Allgemeinmaßnahmen sowie Antihypertensiva zur Verfügung. Bei der Mehrzahl der Hypertoniker gelingt es allein mit Allgemeinmaßnahmen nicht, den Blutdruck ausreichend zu senken. Bei allen Hypertonikern soll der Blutdruck auf <140/90 mmHg gesenkt werden. Bei Diabetikern, Patienten mit Niereninsuffizienz sowie bei Patienten mit Folgekrankheiten der Hypertonie und dadurch sehr hohem kardiovaskulärem Risiko ist der Zielblutdruck <130/80 mmHg. Diuretika, β-Blocker, Kalziumantagonisten, ACE-Inhibitoren und AT1-Antagonisten sind die Antihypertensiva der ersten Wahl. Die Auswahl unter diesen Substanzgruppen erfolgt auf Grund von zu erwartenden Nebenwirkungen sowie unter Berücksichtigung von Begleit- und Folgekrankheiten. Dabei sollte man in Betracht ziehen, dass der wesentliche Nutzen der antihypertensiven Behandlung auf der Blutdrucksenkung an sich beruht und dass die meisten Hypertoniker zum Erreichen des Zielblutdrucks eine Kombination von 2 oder mehr Antihypertensiva benötigen.
Literatur
1.
Zurück zum Zitat ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981–2997CrossRef ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981–2997CrossRef
2.
Zurück zum Zitat Arima H, Chalmers J, Woodward M et al.; PROGRESS Collaborative Group (2006) Lower target blood pressures are safe and effective for the prevention of recurrent stroke: The PROGRESS trial. J Hypertens 24: 1201–1208PubMedCrossRef Arima H, Chalmers J, Woodward M et al.; PROGRESS Collaborative Group (2006) Lower target blood pressures are safe and effective for the prevention of recurrent stroke: The PROGRESS trial. J Hypertens 24: 1201–1208PubMedCrossRef
3.
Zurück zum Zitat Barnett AH, Bain SC, Bouter P et al. (2004) Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351: 1952–1961PubMedCrossRef Barnett AH, Bain SC, Bouter P et al. (2004) Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351: 1952–1961PubMedCrossRef
4.
Zurück zum Zitat Braunwald E, Domanski MJ, Fowler SE et al.; PEACE Trial Investigators (2004) Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351: 2058–2068PubMedCrossRef Braunwald E, Domanski MJ, Fowler SE et al.; PEACE Trial Investigators (2004) Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351: 2058–2068PubMedCrossRef
5.
Zurück zum Zitat Brenner BM, Cooper ME, De Zeeuw D et al.; RENAAL Study Investigators (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861–869PubMedCrossRef Brenner BM, Cooper ME, De Zeeuw D et al.; RENAAL Study Investigators (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861–869PubMedCrossRef
6.
Zurück zum Zitat Casas JP, Chua W, Lukogeorgakis S et al. (2005) Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet 366: 2026–2033PubMedCrossRef Casas JP, Chua W, Lukogeorgakis S et al. (2005) Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet 366: 2026–2033PubMedCrossRef
7.
Zurück zum Zitat Dahlöf B, Sever PS, Poulter NR et al.; ASCOT Investigators (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 366: 895–906PubMedCrossRef Dahlöf B, Sever PS, Poulter NR et al.; ASCOT Investigators (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 366: 895–906PubMedCrossRef
9.
Zurück zum Zitat Elliot WJ, Meyer PM (2007) Incident diabetes in clinical trials of antihypertensive drugs: A network meta- analysis. Lancet 369: 201–207CrossRef Elliot WJ, Meyer PM (2007) Incident diabetes in clinical trials of antihypertensive drugs: A network meta- analysis. Lancet 369: 201–207CrossRef
10.
Zurück zum Zitat Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled multicentre trial (the EUROPA study). Lancet 362: 782–788PubMedCrossRef Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled multicentre trial (the EUROPA study). Lancet 362: 782–788PubMedCrossRef
11.
Zurück zum Zitat Hansson L, Zanchetti A, Carruthers SG et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351: 1755–1762PubMedCrossRef Hansson L, Zanchetti A, Carruthers SG et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351: 1755–1762PubMedCrossRef
12.
Zurück zum Zitat Hou FF, Zhang X, Zhang GH et al. (2006) Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 354: 131–140PubMedCrossRef Hou FF, Zhang X, Zhang GH et al. (2006) Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 354: 131–140PubMedCrossRef
13.
Zurück zum Zitat Ismail AA, Medhat I, Tawfic TA, Kholeif A (1993) Evaluation of calcium-antagonist (nifedipine) in the treatment of pre-eclampsia. Int J Gynaecol Obstet 40: 39–43PubMedCrossRef Ismail AA, Medhat I, Tawfic TA, Kholeif A (1993) Evaluation of calcium-antagonist (nifedipine) in the treatment of pre-eclampsia. Int J Gynaecol Obstet 40: 39–43PubMedCrossRef
14.
Zurück zum Zitat Jafar TH, Stark PC, Schmid CH et al.; AIPRD Study Group (2003) Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. A patient-level meta-analysis. Ann Intern Med 139: 244–252PubMed Jafar TH, Stark PC, Schmid CH et al.; AIPRD Study Group (2003) Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. A patient-level meta-analysis. Ann Intern Med 139: 244–252PubMed
15.
Zurück zum Zitat Jamerson K, Weber MA, Bakris GL et al.; ACCOMPLISH Trial Investigators (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359: 2417–2428PubMedCrossRef Jamerson K, Weber MA, Bakris GL et al.; ACCOMPLISH Trial Investigators (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359: 2417–2428PubMedCrossRef
16.
Zurück zum Zitat Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456–1462PubMedCrossRef Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456–1462PubMedCrossRef
17.
Zurück zum Zitat Lewis EJ, Hunsicker LG, Clarke WR et al. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851–860PubMedCrossRef Lewis EJ, Hunsicker LG, Clarke WR et al. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851–860PubMedCrossRef
18.
Zurück zum Zitat Lindholm LH, Carlberg B, Samuelsson O (2005) Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366: 1545–1553PubMedCrossRef Lindholm LH, Carlberg B, Samuelsson O (2005) Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366: 1545–1553PubMedCrossRef
19.
Zurück zum Zitat Magee LA, Elran E, Bull SB et al. (2000) Risks and benefits of beta-receptor blockers for pregnancy hypertension: Overview of the randomized trials. Eur J Obstet Gynecol Reprod Biol 88: 15–26PubMedCrossRef Magee LA, Elran E, Bull SB et al. (2000) Risks and benefits of beta-receptor blockers for pregnancy hypertension: Overview of the randomized trials. Eur J Obstet Gynecol Reprod Biol 88: 15–26PubMedCrossRef
20.
Zurück zum Zitat Mancia G, De Backer G, Dominiczak A et al. (2007) Guidelines for the management of arterial hypertension. J Hypertens 25: 1105–1187PubMedCrossRef Mancia G, De Backer G, Dominiczak A et al. (2007) Guidelines for the management of arterial hypertension. J Hypertens 25: 1105–1187PubMedCrossRef
21.
Zurück zum Zitat Medical Research Council Working Party (1985) MRC trial of mild hypertension: Principal results. BMJ (Clin Res Ed) 291: 97–104 Medical Research Council Working Party (1985) MRC trial of mild hypertension: Principal results. BMJ (Clin Res Ed) 291: 97–104
22.
Zurück zum Zitat Messerli FH, Mancia G, Conti CR et al. (2006) Dogma disputed: Can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 144: 884–893PubMed Messerli FH, Mancia G, Conti CR et al. (2006) Dogma disputed: Can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 144: 884–893PubMed
23.
Zurück zum Zitat Mogensen CE (1982) Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 285: 685–688PubMedCrossRef Mogensen CE (1982) Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 285: 685–688PubMedCrossRef
24.
Zurück zum Zitat ONTARGET Investigators, Yusuf S, Teo KK, Pogue J et al. (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547–1559CrossRef ONTARGET Investigators, Yusuf S, Teo KK, Pogue J et al. (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547–1559CrossRef
25.
Zurück zum Zitat Patel A, MacMahon S, Chalmers J et al.; ADVANCE Collaborative Group (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet 370: 829–840PubMedCrossRef Patel A, MacMahon S, Chalmers J et al.; ADVANCE Collaborative Group (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet 370: 829–840PubMedCrossRef
26.
Zurück zum Zitat Pepine CJ, Handberg EM, Cooper-DeHoff RM et al.; INVEST Investigators (2003) A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 290: 2805–2816PubMedCrossRef Pepine CJ, Handberg EM, Cooper-DeHoff RM et al.; INVEST Investigators (2003) A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 290: 2805–2816PubMedCrossRef
27.
Zurück zum Zitat Peterson JC, Adler S, Burkart JM et al. (1995) Blood pressure control, proteinuria,and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123: 754–762PubMed Peterson JC, Adler S, Burkart JM et al. (1995) Blood pressure control, proteinuria,and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123: 754–762PubMed
28.
Zurück zum Zitat PROGRESS Collaborative Study Group (2001) Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033–1041CrossRef PROGRESS Collaborative Study Group (2001) Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033–1041CrossRef
29.
Zurück zum Zitat Turnbull F; Blood Pressure Lowering Treatment Trialists‘ Collaboration (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet 362: 1527–1535PubMedCrossRef Turnbull F; Blood Pressure Lowering Treatment Trialists‘ Collaboration (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet 362: 1527–1535PubMedCrossRef
Metadaten
Titel
Leitliniengerechte Differenzialtherapie der Hypertonie
verfasst von
Prof. Dr. K.H. Rahn
Publikationsdatum
01.04.2009
Verlag
Springer-Verlag
Erschienen in
Die Innere Medizin / Ausgabe 4/2009
Print ISSN: 2731-7080
Elektronische ISSN: 2731-7099
DOI
https://doi.org/10.1007/s00108-008-2292-8

Weitere Artikel der Ausgabe 4/2009

Die Innere Medizin 4/2009 Zur Ausgabe

Schwerpunkt: Hypertonie

Schlaganfall und Hypertonie

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.